Localization of Transforming Growth Factor-β1 and Receptor mRNA after Experimental Spinal Cord Injury

doi:10.1006/exnr.2000.7372

Experimental Neurology

Volume 163, Issue 1, May 2000, Pages 220-230

https://doi.org/10.1006/exnr.2000.7372 Get rights and content

Abstract

Transforming growth factor-β1 (TGFβ1) is a cytokine/growth factor found within the pathological central nervous system. TGFβ1 has been shown to inhibit the release of cytotoxic molecules from microglia and macrophages, decrease astrocyte proliferation, and promote neuron survival. Because of the relevance of these actions to spinal cord injury, we examined TGFβ1 and its receptors βRI and βRII mRNA levels and localization within the contused rat spinal cord using in situ hybridization. At the lesion site, TGFβ1 mRNA peaked at 7 days postinjury and declined thereafter. Temporal and spatial localization of the βRI and βRII receptor mRNA closely mimicked that for TGFβ1 in the epicenter. TGFβ1, βRI, and βRII mRNAs also were elevated rostral and caudal to the injury, especially in regions known to contain activated microglia and degenerating axon profiles. Immunohistochemical staining of nearby sections confirmed that the highest levels of TGFβ1 and receptor mRNA corresponded to regions filled with activated microglia and macrophages. The similar expression pattern of TGFβ1, βRI, and βRII mRNA within the injured spinal cord suggests a local site of action. Since TGFβ1 can act as an immunosuppressant as well as a stimulant for growth factors and neurite sprouting, it likely plays an important role, both temporally and spatially, in orchestrating postinjury events within the spinal cord.

References (66)

A.R. Blight
Effects of silica on the outcome from experimental spinal cord injury: Implication of macrophages in secondary tissue damage
Neuroscience
(1994)
J.C. Bresnahan et al.
A behavioral and anatomical analysis of spinal cord injury produced by a feedback-controlled impaction device
Exp. Neurol.
(1987)
B. Chamak et al.
Immunohistochemical detection of thrombospondin in microglia in the developing rat brain
Neuroscience
(1995)
R Derynck
TGF-β-receptor-mediated signaling
Trends. Biochem. Sci.
(1994)
K.C. Flanders et al.
Transforming growth factor-βs in neurodegenerative disease
Prog. Neurobiol.
(1998)
P. Franzen et al.
Cloning of TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor
Cell
(1993)
Y. Hamada et al.
Effects of exogenous transforming growth factor-β1 on spinal cord injury in rats
Neurosci. Lett.
(1996)
A. Ishihara et al.
Transforming growth factor-beta 1 and -beta 2 promote neurite sprouting and elongation of cultured rat hippocampal neurons
Brain Res.
(1994)
K. Krohn et al.
Expression of vimentin increases in the hippocampus and cerebral cortex after entorhinal cortex lesioning and in response to transforming growth factor β1
J. Neuroimmunol.
(1995)
N.J. Laping et al.
Transforming growth factor-β1 induces neuronal and astrocyte genes: Tubulin α1, glial fibrillary acidic protein and clusterin
Neuroscience
(1994)

E. Lehrmann et al.

Cytokines in cerebral ischemia: Expression of transforming growth factor beta-1 (TGF-β1) mRNA in the postischemic adult rat hippocampus

Exp. Neurol.

(1995)

M. Lorentzon et al.

Habrec1, a novel serine/threonine kinase TGF-β type I-like receptor, has a specific cellular expression suggesting function in the developing organism and adult brain

Exp. Neurol.

(1996)

J Massagué

Receptors for the TGF-β family

Cell

(1992)

T.E. Morgan et al.

TGF-β1 mRNA increases in macrophage/microglial cells of the hippocampus in response to deafferentation and kainic acid-induced neurodegeneration

Exp. Neurol.

(1993)

K.M. Neugebauer et al.

Vitronectin and thrombospondin promote retinal neurite outgrowth: Developmental regulation and role of integrins

Neuron

(1991)

K.S. O'Shea et al.

Thrombospondin and a 140 kd fragment promote adhesion and neurite outgrowth from embryonic central and peripheral neurons and from PC12 cells

Neuron

(1991)

P.G. Popovich et al.

Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury

Exp. Neurol.

(1999)

J.H. Prehn et al.

Opposing effects of transforming growth factor-beta 1 on glutamate neurotoxicity

Neuroscience

(1994)

J.H.M. Prehn et al.

Opposite effects of TGF-β1 on rapidly- and slowly-triggered excitotoxic injury

Neuropharmacology

(1996)

S. Schultz-Cherry et al.

The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-β

J. Biol. Chem.

(1994)

S. Schultz-Cherry et al.

Thrombospondin binds and activates the small and large forms of latent transforming growth factor-β in a chemically defined system

J. Biol. Chem.

(1994)

T.A. Slotkin et al.

Expression of mRNAs coding for the transforming growth factor-β receptors in brain regions of euthyroid and hypothyroid neonatal rats and in adult brain

Dev. Brain Res.

(1997)

W.J. Streit et al.

Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis

Exp. Neurol.

(1998)

K. Tsuchida et al.

Molecular characterization of rat transforming growth factor-beta type II receptor

Biochem. Biophys. Res. Commun.

(1993)

K. Tsuchida et al.

Molecular cloning of a novel type I receptor serine/threonine kinase for the TGFβ superfamily from rat brain

Mol. Cell. Neurosci.

(1996)

K. Unsicker et al.

Transforming growth factor beta isoforms in the adult rat central and peripheral nervous system

Neuroscience

(1991)

L.M. Wakefield et al.

Latent transforming growth factor-β from human platelets

J. Biol. Chem.

(1988)

J.L. Wrana et al.

TGFβ signals through a heteromeric protein kinase receptor complex

Cell

(1992)

Z. Zhang et al.

Experimental analysis of progressive necrosis after spinal cord trauma in the rat: Etiological role of the inflammatory response

Exp. Neurol.

(1997)

A.A. Alousi et al.

Pharmacology of the bipyridines: Amrinone and milrinone

Circulation

(1986)

D. Baghdassarian et al.

Effects of transforming growth factor-β 1 on the extracellular matrix and cytoskeleton of cultured astrocytes

GLIA

(1993)

M. Bottner et al.

Expression of TGF-beta type II receptor mRNA in the CNS

Neuroreport

(1996)

Cited by (81)

Human umbilical cord blood-derived platelet -rich plasma: a new window for motor function recovery and axonal regeneration after spinal cord injury
2022, Physiology and Behavior
Citation Excerpt :
All of them have mentioned that GFs were lead to remyelination, neural regeneration, and motor function recovery and prevented apoptosis. For example, Transforming growth factor-β (TGF-β) improves the synthesis of extracellular matrix components and promotes neuron survival [10]. In vitro study showed Insulin-like growth factor-I (IGF1) specifically enhances the outgrowth of corticospinal motor neuron's axons [9].
There are complex mechanisms for reducing intrinsic repairability and neuronal regeneration following spinal cord injury (SCI). Platelet-rich plasma (PRP) is a rich source of growth factors and has been used to motivate the regeneration of peripheral nerves in neurodegenerative disorders. However, only a few studies have shown the effects of PRP on the SCI models.
We investigated whether PRP derived from human umbilical cord blood (HUCB-PRP) could recover motor function in animals with spinal cord injury. Sixty adult male Wistar rats were randomly divided into 6 groups (n=60) as control, sham (laminectomy without induction of spinal cord injury), SCI, vehicle (SCI+ Platelet-Poor Plasma), PRP2day (SCI+PRP injection 2 days after SCI), and PRP14day (SCI+PRP injection 14 days after SCI). SCI was performed at the T12-T13 level. BBB test was carried out weekly after injury for six weeks. Caspase3 expression was determined using the Immunohistochemistry technique. The expression of GSK3β, CSF-tau, and MAG was determined using the Western blot technique. Data were analyzed by PRISM & SPSS software.
HUCB-PRP treated animals showed a higher locomotor function recovery than those in the SCI group (p<0.0001). The level of caspase3, GSK3β and CSF- Tau reduced and the MAG level in the spinal cord increased by the injection of HUCB-PRP in SCI animals.
Injection of HUCB-PRP enhanced hind limb locomotor performance by modulation of caspase3, GSK3β, CSF-tau, and MAG expression. Using HUCB-PRP could be a new therapeutic option for recovering motor function and axonal regeneration after SCI.
Does physical exercise influence in the development of neuroeschistosomiasis?
2019, Brain Research Bulletin
Neuroschistosomiasis is a severe form of presentation of schistosomiasis in which Schistosoma spp. affects the central nervous system. This is the first study performed to analyze whether there is any relationship between physical effort and the appearance of neuroschistosomiasis, through clinical, molecular and immunological evaluations. An experimental controlled study using 64 male Balb/c inbred mice divided into four groups according to presence or absence of S. mansoni infection and submitted to physical effort or resting was conducted. Thirteen weeks after exercise training, S. mansoni DNA was detected in the brain or spinal cord in about 30% of the infected animals moreover, only S. mansoni-positive samples showed positive labeling for S. mansoni antigens in the brain or spinal cord, with a striking reaction inside the microglia. However, the behavioral tests did not show any clinical symptoms of neuroschistosomiasis in animals submitted to physical effort or in resting. In animals with S. mansoni-positive DNA, immunohistochemical data revealed astrogliosis and microgliosis, elevated IL-10 levels and decreased TNF-α expression. This study demonstrated that isometric exercise does not promote neuroschistosomiasis, furthermore, ectopic forms of schistosomiasis in the central nervous system were largely asymptomatic and exhibited a Th2 immune response profile. More experimental studies are necessary in order to characterize the pathological process of experimental neuroschistosomiasis.
Extracellular matrix regulation of inflammation in the healthy and injured spinal cord
2014, Experimental Neurology
Throughout the body, the extracellular matrix (ECM) provides structure and organization to tissues and also helps regulate cell migration and intercellular communication. In the injured spinal cord (or brain), changes in the composition and structure of the ECM undoubtedly contribute to regeneration failure. Less appreciated is how the native and injured ECM influences intraspinal inflammation and, conversely, how neuroinflammation affects the synthesis and deposition of ECM after CNS injury. In all tissues, inflammation can be initiated and propagated by ECM disruption. Molecules of ECM newly liberated by injury or inflammation include hyaluronan fragments, tenascins, and sulfated proteoglycans. These act as “damage-associated molecular patterns” or “alarmins”, i.e., endogenous proteins that trigger and subsequently amplify inflammation. Activated inflammatory cells, in turn, further damage the ECM by releasing degradative enzymes including matrix metalloproteinases (MMPs). After spinal cord injury (SCI), destabilization or alteration of the structural and chemical compositions of the ECM affects migration, communication, and survival of all cells – neural and non-neural – that are critical for spinal cord repair. By stabilizing ECM structure or modifying their ability to trigger the degradative effects of inflammation, it may be possible to create an environment that is more conducive to tissue repair and axon plasticity after SCI.
Cytokine pathways regulating glial and leukocyte function after spinal cord and peripheral nerve injury
2014, Experimental Neurology
Injury to the nervous system causes the almost immediate release of cytokines by glial cells and neurons. These cytokines orchestrate a complex array of responses leading to microgliosis, immune cell recruitment, astrogliosis, scarring, and the clearance of cellular debris, all steps that affect neuronal survival and repair. This review will focus on cytokines released after spinal cord and peripheral nerve injury and the primary signalling pathways triggered by these inflammatory mediators. Notably, the following cytokine families will be covered: IL-1, TNF, IL-6-like, TGF-β, and IL-10. Whether interfering with cytokine signalling could lead to novel therapies will also be discussed. Finally, the review will address whether manipulating the above-mentioned cytokine families and signalling pathways could exert distinct effects in the injured spinal cord versus peripheral nerve.
Identification of key autophagy-related genes and pathways in spinal cord injury
2024, Scientific Reports
TGF-β signaling pathway in spinal cord injury: Mechanisms and therapeutic potential
2024, Journal of Neuroscience Research

View all citing articles on Scopus

View full text

Regular ArticleLocalization of Transforming Growth Factor-β1 and Receptor mRNA after Experimental Spinal Cord Injury

Abstract

Neuroscience

Exp. Neurol.

Neuroscience

Trends. Biochem. Sci.

Prog. Neurobiol.

Cell

Neurosci. Lett.

Brain Res.

J. Neuroimmunol.

Neuroscience

Exp. Neurol.

Exp. Neurol.

Cell

Exp. Neurol.

Neuron

Neuron

Exp. Neurol.

Neuroscience

Neuropharmacology

J. Biol. Chem.

J. Biol. Chem.

Dev. Brain Res.

Exp. Neurol.

Biochem. Biophys. Res. Commun.

Mol. Cell. Neurosci.

Neuroscience

J. Biol. Chem.

Cell

Exp. Neurol.

Pharmacology of the bipyridines: Amrinone and milrinone

Circulation

Effects of transforming growth factor-β 1 on the extracellular matrix and cytoskeleton of cultured astrocytes

GLIA

Expression of TGF-beta type II receptor mRNA in the CNS

Neuroreport

Regular Article
Localization of Transforming Growth Factor-β1 and Receptor mRNA after Experimental Spinal Cord Injury